Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brachytherapy | 50 | 2024 | 1222 | 7.280 |
Why?
|
Prostatic Neoplasms | 78 | 2024 | 11083 | 3.990 |
Why?
|
Prostate-Specific Antigen | 23 | 2024 | 2464 | 1.870 |
Why?
|
Androgen Antagonists | 20 | 2024 | 1411 | 1.560 |
Why?
|
Radiation Oncology | 13 | 2022 | 569 | 1.430 |
Why?
|
Palladium | 8 | 2015 | 67 | 1.040 |
Why?
|
Hyaluronic Acid | 3 | 2024 | 484 | 0.900 |
Why?
|
Radioisotopes | 8 | 2021 | 495 | 0.710 |
Why?
|
Rectum | 8 | 2024 | 896 | 0.680 |
Why?
|
Prostatectomy | 12 | 2024 | 1782 | 0.670 |
Why?
|
Radiotherapy Dosage | 20 | 2024 | 2865 | 0.640 |
Why?
|
Radiotherapy | 4 | 2023 | 1494 | 0.620 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2021 | 2047 | 0.560 |
Why?
|
Neoplasms, Second Primary | 3 | 2021 | 1050 | 0.530 |
Why?
|
Radiometry | 4 | 2024 | 804 | 0.460 |
Why?
|
Rectal Diseases | 2 | 2012 | 141 | 0.430 |
Why?
|
Prostate | 12 | 2024 | 1755 | 0.420 |
Why?
|
Radiosurgery | 4 | 2021 | 1328 | 0.400 |
Why?
|
Iodine Radioisotopes | 5 | 2013 | 1029 | 0.400 |
Why?
|
Catheters, Indwelling | 1 | 2014 | 438 | 0.370 |
Why?
|
Male | 83 | 2024 | 363698 | 0.360 |
Why?
|
Academic Medical Centers | 4 | 2017 | 2780 | 0.350 |
Why?
|
Aged | 55 | 2024 | 171117 | 0.340 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2024 | 1643 | 0.340 |
Why?
|
Quality of Life | 4 | 2023 | 13462 | 0.330 |
Why?
|
Radiation Dosage | 3 | 2023 | 1944 | 0.310 |
Why?
|
Urination | 1 | 2009 | 204 | 0.290 |
Why?
|
Databases, Factual | 10 | 2019 | 8067 | 0.290 |
Why?
|
Humans | 97 | 2024 | 765968 | 0.270 |
Why?
|
Middle Aged | 45 | 2024 | 223009 | 0.270 |
Why?
|
Neoplasm Staging | 9 | 2024 | 11206 | 0.260 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2023 | 784 | 0.260 |
Why?
|
Particle Accelerators | 1 | 2006 | 174 | 0.260 |
Why?
|
Radiation Injuries | 3 | 2023 | 1181 | 0.250 |
Why?
|
Gamma Rays | 1 | 2006 | 324 | 0.240 |
Why?
|
Utilization Review | 2 | 2016 | 381 | 0.230 |
Why?
|
Retrospective Studies | 24 | 2024 | 81514 | 0.230 |
Why?
|
Combined Modality Therapy | 5 | 2019 | 8529 | 0.220 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2021 | 1776 | 0.220 |
Why?
|
Intracranial Arteriovenous Malformations | 1 | 2006 | 360 | 0.210 |
Why?
|
Fluoroscopy | 1 | 2007 | 947 | 0.210 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2895 | 0.210 |
Why?
|
Urinary Bladder | 1 | 2009 | 1154 | 0.210 |
Why?
|
Survival Rate | 10 | 2020 | 12795 | 0.210 |
Why?
|
SEER Program | 6 | 2019 | 1446 | 0.210 |
Why?
|
Risk Assessment | 11 | 2020 | 24282 | 0.200 |
Why?
|
Spermatic Cord | 1 | 2002 | 23 | 0.200 |
Why?
|
Travel | 2 | 2018 | 806 | 0.190 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 2002 | 66 | 0.190 |
Why?
|
Genital Diseases, Male | 1 | 2002 | 84 | 0.190 |
Why?
|
Salvage Therapy | 3 | 2023 | 1272 | 0.190 |
Why?
|
Tumor Burden | 2 | 2024 | 1885 | 0.190 |
Why?
|
Prognosis | 12 | 2024 | 29922 | 0.190 |
Why?
|
Magnetic Resonance Imaging | 6 | 2023 | 36532 | 0.170 |
Why?
|
Internship and Residency | 2 | 2019 | 5946 | 0.170 |
Why?
|
Phyllodes Tumor | 1 | 2020 | 54 | 0.170 |
Why?
|
Antineoplastic Agents | 4 | 2024 | 13648 | 0.160 |
Why?
|
Pelvis | 1 | 2024 | 738 | 0.160 |
Why?
|
Proportional Hazards Models | 6 | 2019 | 12509 | 0.160 |
Why?
|
Watchful Waiting | 3 | 2018 | 493 | 0.160 |
Why?
|
Healthcare Disparities | 4 | 2021 | 3413 | 0.150 |
Why?
|
Uveal Neoplasms | 1 | 2021 | 343 | 0.150 |
Why?
|
Adenocarcinoma | 5 | 2015 | 6364 | 0.140 |
Why?
|
Disease-Free Survival | 8 | 2017 | 6832 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2023 | 9373 | 0.130 |
Why?
|
Kallikreins | 1 | 2018 | 220 | 0.130 |
Why?
|
Follow-Up Studies | 12 | 2019 | 39193 | 0.130 |
Why?
|
Societies, Medical | 4 | 2022 | 3956 | 0.130 |
Why?
|
Cancer Care Facilities | 2 | 2017 | 426 | 0.130 |
Why?
|
Survival Analysis | 6 | 2018 | 10070 | 0.130 |
Why?
|
United States | 20 | 2022 | 72903 | 0.120 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 830 | 0.120 |
Why?
|
Prospective Studies | 12 | 2023 | 54802 | 0.120 |
Why?
|
Refugees | 1 | 2023 | 614 | 0.120 |
Why?
|
Treatment Outcome | 12 | 2021 | 65188 | 0.120 |
Why?
|
Genital Neoplasms, Female | 1 | 2019 | 533 | 0.110 |
Why?
|
Neoplasms | 5 | 2022 | 22340 | 0.110 |
Why?
|
Needles | 1 | 2017 | 460 | 0.110 |
Why?
|
Neck | 1 | 2018 | 733 | 0.110 |
Why?
|
Middle East | 2 | 2024 | 237 | 0.110 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1668 | 0.100 |
Why?
|
Quality Assurance, Health Care | 2 | 2020 | 2172 | 0.100 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2659 | 0.100 |
Why?
|
Absorbable Implants | 1 | 2015 | 333 | 0.100 |
Why?
|
Organs at Risk | 1 | 2014 | 352 | 0.100 |
Why?
|
Risk Factors | 12 | 2024 | 74840 | 0.100 |
Why?
|
Consensus | 1 | 2021 | 3202 | 0.090 |
Why?
|
Kinetics | 1 | 2019 | 6274 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3946 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4893 | 0.090 |
Why?
|
Defecation | 1 | 2012 | 190 | 0.090 |
Why?
|
Canada | 1 | 2016 | 2119 | 0.090 |
Why?
|
Logistic Models | 7 | 2019 | 13266 | 0.090 |
Why?
|
Aged, 80 and over | 12 | 2023 | 59489 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6499 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4058 | 0.080 |
Why?
|
Edema | 1 | 2013 | 760 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 3537 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2017 | 1534 | 0.080 |
Why?
|
Health Personnel | 2 | 2020 | 3390 | 0.080 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1394 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2535 | 0.080 |
Why?
|
Cohort Studies | 6 | 2020 | 41649 | 0.080 |
Why?
|
Radiation Protection | 1 | 2012 | 424 | 0.080 |
Why?
|
Ultrasonography | 2 | 2014 | 5993 | 0.070 |
Why?
|
Urodynamics | 1 | 2009 | 349 | 0.070 |
Why?
|
Medicare | 2 | 2021 | 6823 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2012 | 1188 | 0.070 |
Why?
|
Socioeconomic Factors | 5 | 2021 | 7838 | 0.070 |
Why?
|
Propensity Score | 3 | 2021 | 1968 | 0.060 |
Why?
|
Urethra | 2 | 2021 | 406 | 0.060 |
Why?
|
Ultrasonography, Interventional | 1 | 2014 | 1531 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2020 | 4300 | 0.060 |
Why?
|
Physical Phenomena | 1 | 2024 | 48 | 0.060 |
Why?
|
Iraq | 1 | 2024 | 93 | 0.060 |
Why?
|
Lymphatic Irradiation | 1 | 2024 | 110 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3230 | 0.050 |
Why?
|
Feasibility Studies | 3 | 2023 | 5302 | 0.050 |
Why?
|
Androgens | 2 | 2024 | 1279 | 0.050 |
Why?
|
Lebanon | 1 | 2024 | 246 | 0.050 |
Why?
|
Syria | 1 | 2023 | 88 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5526 | 0.050 |
Why?
|
Health Care Costs | 1 | 2016 | 3242 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3100 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3223 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5370 | 0.050 |
Why?
|
Time Factors | 5 | 2019 | 40065 | 0.050 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12056 | 0.050 |
Why?
|
Radiotherapy, High-Energy | 1 | 2002 | 226 | 0.050 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2017 | 869 | 0.050 |
Why?
|
Intracranial Hemorrhages | 1 | 2006 | 814 | 0.050 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2008 | 1127 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5508 | 0.040 |
Why?
|
Genomics | 1 | 2017 | 5929 | 0.040 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1628 | 0.040 |
Why?
|
Taxoids | 1 | 2024 | 665 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8703 | 0.040 |
Why?
|
Orchiectomy | 1 | 2002 | 460 | 0.040 |
Why?
|
North America | 1 | 2023 | 1285 | 0.040 |
Why?
|
Adult | 11 | 2024 | 223044 | 0.040 |
Why?
|
Incidence | 4 | 2023 | 21480 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 893 | 0.040 |
Why?
|
Stromal Cells | 1 | 2024 | 1329 | 0.040 |
Why?
|
Female | 11 | 2021 | 396112 | 0.040 |
Why?
|
Gastrointestinal Tract | 1 | 2024 | 834 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 4 | 2008 | 20659 | 0.040 |
Why?
|
Patient Selection | 2 | 2022 | 4255 | 0.040 |
Why?
|
Biopsy | 3 | 2015 | 6763 | 0.030 |
Why?
|
Predictive Value of Tests | 4 | 2018 | 15398 | 0.030 |
Why?
|
Europe | 1 | 2023 | 3423 | 0.030 |
Why?
|
Organizational Case Studies | 1 | 2017 | 299 | 0.030 |
Why?
|
Regression Analysis | 2 | 2016 | 6322 | 0.030 |
Why?
|
Accreditation | 1 | 2019 | 477 | 0.030 |
Why?
|
Fee-for-Service Plans | 1 | 2021 | 716 | 0.030 |
Why?
|
Cryotherapy | 1 | 2017 | 164 | 0.030 |
Why?
|
Treatment Failure | 2 | 2015 | 2652 | 0.030 |
Why?
|
Reimbursement Mechanisms | 1 | 2021 | 672 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 299 | 0.030 |
Why?
|
Gastrointestinal Diseases | 1 | 2024 | 1203 | 0.030 |
Why?
|
Reactive Oxygen Species | 1 | 2023 | 2140 | 0.030 |
Why?
|
Data Display | 1 | 2016 | 174 | 0.030 |
Why?
|
Benchmarking | 1 | 2021 | 1052 | 0.030 |
Why?
|
Mastectomy, Segmental | 1 | 2020 | 964 | 0.030 |
Why?
|
Odds Ratio | 2 | 2017 | 9649 | 0.030 |
Why?
|
Clinical Competence | 2 | 2020 | 4863 | 0.030 |
Why?
|
Morbidity | 1 | 2019 | 1749 | 0.030 |
Why?
|
Radiation, Ionizing | 1 | 2015 | 249 | 0.030 |
Why?
|
Algorithms | 2 | 2021 | 14071 | 0.030 |
Why?
|
Testosterone | 1 | 2024 | 2494 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 2015 | 445 | 0.030 |
Why?
|
Marital Status | 1 | 2015 | 426 | 0.030 |
Why?
|
Community Health Centers | 1 | 2017 | 469 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2020 | 21056 | 0.030 |
Why?
|
Lymph Nodes | 1 | 2024 | 3454 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2014 | 15747 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2021 | 1806 | 0.020 |
Why?
|
Mastectomy | 1 | 2020 | 1847 | 0.020 |
Why?
|
Registries | 2 | 2019 | 8297 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2017 | 1405 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2015 | 1326 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2015 | 2910 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 3236 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1429 | 0.020 |
Why?
|
Medical Oncology | 1 | 2021 | 2339 | 0.020 |
Why?
|
Equipment Design | 1 | 2017 | 3481 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2020 | 2778 | 0.020 |
Why?
|
Health Expenditures | 1 | 2021 | 2387 | 0.020 |
Why?
|
Uterine Neoplasms | 1 | 2017 | 1421 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9525 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2024 | 8611 | 0.020 |
Why?
|
Organ Size | 1 | 2013 | 2260 | 0.020 |
Why?
|
Medicaid | 1 | 2021 | 2833 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3708 | 0.020 |
Why?
|
Hydrogels | 1 | 2012 | 728 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5876 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1458 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2017 | 3564 | 0.020 |
Why?
|
Young Adult | 2 | 2015 | 59889 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2015 | 2243 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9591 | 0.010 |
Why?
|
Software | 1 | 2017 | 4462 | 0.010 |
Why?
|
Radiology | 1 | 2017 | 2090 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 26318 | 0.010 |
Why?
|
Physicians | 1 | 2020 | 4588 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8875 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18380 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13632 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16721 | 0.010 |
Why?
|
Child | 1 | 2006 | 80564 | 0.010 |
Why?
|
Adolescent | 1 | 2006 | 88835 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2006 | 6203 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 18071 | 0.010 |
Why?
|
Concepts
(212)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(47)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_